Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus QUINAGLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus QUINAGLUTE.
CIN-QUIN vs QUINAGLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Class Ia antiarrhythmic agent; binds to sodium channels and inhibits the fast inward sodium current, slowing phase 0 depolarization and prolonging the action potential duration. Also exhibits anticholinergic and negative inotropic effects.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
324-648 mg orally every 8-12 hours; extended-release formulation (quinidine gluconate).
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal elimination half-life is 5-7 hours in adults with normal renal function. In hepatic impairment, half-life may increase to 12-24 hours; in severe renal impairment (CrCl <10 mL/min), half-life may exceed 24 hours.
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of total clearance. Biliary/fecal excretion contributes about 20-30%. Acidic urine increases renal clearance.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)